Ferroportin downregulation promotes cell proliferation by modulating the Nrf2-miR-17-5p axis in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Aberrant downregulation of ferroportin (FPN1) is linked to poor prognosis and osteoclast differentiation in multiple myeloma (MM).
• Understanding the regulatory mechanisms of FPN1 in MM is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of FPN1 downregulation in MM progression.
• To identify and characterize regulators of FPN1, including microRNAs and transcription factors.
• To explore the therapeutic potential of targeting FPN1 in MM.

Main Methods:

• CRISPR-mediated FPN1 knockout in MM cells.
• MicroRNA target-scan algorithm to identify FPN1 regulators.
• In vitro and in vivo experiments using MM cell lines and xenograft models.
• Bioinformatics analysis, chromatin immunoprecipitation-polymerase chain reaction, and luciferase assays to study transcription factor binding and activity.

Main Results:

• FPN1 was downregulated in MM, and its knockout promoted MM cell growth and survival.
• miR-17-5p was identified as an FPN1 regulator that promotes MM cell proliferation, cell cycle progression, and inhibits apoptosis.
• Nrf2 transcriptionally drove FPN1 expression while suppressing miR-17-5p, impacting intracellular iron and reactive oxygen species levels.
• Restoring FPN1 expression partially abrogated miR-17-5p's effects in MM cells.

Conclusions:

• FPN1 downregulation is a key driver of MM cell growth and survival.
• miR-17-5p and Nrf2 are critical regulators of FPN1, influencing cellular iron homeostasis and oxidative stress.
• FPN1 represents a promising prognostic marker and therapeutic target for multiple myeloma.